Welcome to the international HTA database

Showing [20545 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]
2012	Finnish Office for Health Care Technology Assessment (Finohta)	[Magnetic resonance imaging of primary breast cancer]
2008	Committee for New Health Technology Assessment (CNHTA)	[Magnetic Resonance Imaging guided high intensity Focused Ultrasound Surgery(MRgFUS) using ExAblate 2000 equipment]
2008	Andalusian Health Technology Assessment Area (AETSA)	[Magnetic Resonance imaging for breast cancer diagnostics. Systematic review and economic assessment]
2012	Andalusian Health Technology Assessment Area (AETSA)	[Magnetic resonance guided focused ultrasound for uterine myomas ablation]
2009	Committee for New Health Technology Assessment (CNHTA)	[Magnetic remote controlled catheter navigation technique]
2015	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	[Magnetic growth rods for the scoliosis treatment in children]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Macitentan (pulmonary arterial hypertension) - Benefit assessment according to §35a Social Code Book V]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Macitentan - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2019	Haute Autorite de sante (HAS)	[Lymphoseek (tilmanocept), radiopharmaceutical for diagnostic use]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lutetium-177 radiolabeled somatostatin analogs in neuroendocrine tumors]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lutetium 177 PSMA in patients with prostate cancer]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lusotrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lurasidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Lung cancer: investigation, treatment and follow-up algorithms]
2009	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Lung cancer screening]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lung cancer screening using low-dose computed tomography]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	[Lung cancer screening in risk groups]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumasiran (hyperoxaluria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lumacaftor/Ivacaftor therapy in cystic fibrosis]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis, homozygous F508del mutation in the CFTR gene, 2-5 years) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)]
2019	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Lower Urinary Tract Symptoms - epidemiology and results from LUTS project Funen on implementation of a clinical guideline in general practice]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Lower respiratory tract infections of a viral origin in the paediatric population: systematic review of Spanish literature]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Low-intensity ultrasound for the treatment of fractures]
2016	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Low-dose computed tomography screening for lung cancer]
1999	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Low-back pain: frequency, management and prevention from an HTA perspective]
2002	Basque Office for Health Technology Assessment (OSTEBA)	[Low molecular weight heparins versus traditional heparins in thromboembolic diseases]
2011	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Low density lipoprotein apheresis as adjuvant treatment for familial hypercholesterolaemia]
2019	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lonoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2008	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Longevity of dental amalgam in comparison to composite materials]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[Long-term safety and stability of refractive surgeries in myopia]
2009	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Long-acting insulin analogues in the treatment of diabetes mellitus type 2]
2010	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Long-acting insulin analogues in the treatment of diabetes mellitus type 1]
2007	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Long term substitution treatment (maintenance treatment) of opioid dependent persons]
2009	Finnish Office for Health Care Technology Assessment (Finohta)	[Long term sensors for measuring blood sugar]
2009	Norwegian Knowledge Centre for the Health Services (NOKC)	[Long term institutional or residential treatment of patients with substance abuse compared to short-term outpatient treatment]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lomitapide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lomitapide - Addendum to Commission A15-23]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Localized prostate cancer: effectiveness and safety of treatment options]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Localized and disseminated stages of Lyme disease: from diagnosis to treatment, report in support of the diagnosis and treatment decision support tools]
2015	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Local injection therapy with bulking agents for faecal incontinence]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lixisenatide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2007	Health Council of the Netherlands Gezondheidsraad (GR)	[Living donor list exchange: an addition to the Dutch living kidney donor programme?]
2010	Committee for New Health Technology Assessment (CNHTA)	[Liver cancer prognostic marker(OncoHepa)]
2012	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Literature search and evidence assessment to examine the effects of regulations for minimum volumes (acc. to §6 [5], line 2 of the directive on outpatient treatment in hospitals acc. to §116b Social Code Book V) - Rapid report]
2011	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Literature review of organisational and patient aspects in HTA]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Literature bibliographic search protocols adapting them to the different search outputs]
2012	Norwegian Knowledge Centre for the Health Services (NOKC)	[List size and quality of care among GPs within The Regular General Practitioner Scheme]
2023	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2019	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisdexamfetamine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Liraglutide in obese and overweight patients]
2008	The Regional Health Technology Assessment Centre (HTA-centrum)	[Liquid-based cytology for screening of precursors of cervical cancer]
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Liquid biopsy utility in the colorectal cancer's management stages I-IV]
2020	Canary Health Service	[Liquid biopsy for the detection of ovarian or endometrial cancer in samples taken from the Pap smear: PapSEEK]
2008	Committee for New Health Technology Assessment (CNHTA)	[Liqui-Prep TM]
2021	Norwegian Institute of Public Health (NIPH)	[Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Liposomal combination of cytarabine and daunorubicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Lipoedema – diagnosis, treatment, and experiences]
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Lipid metabolism disorders: review of the indications of fat free dietetic products and nutritional alternatives with regularly consumed foodstuffs]
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Linear accelerator radiosurgery for trigeminal neuralgia]
2012	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)]
2011	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Linagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Linaclotide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2010	Institute for Clinical Effectiveness and Health Policy (IECS)	[Levonorgestrel-releasing intrauterine device (IUD) for patients with hypermenorrhea]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12]
2015	Institut national d'excellence en sante et en services sociaux (INESSS)	[Levels of medical intervention -- levels of care]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Levels of care: norms and quality standards]
2006	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Leukotriene receptor antagonists in patients with asthma]
2009	The Swedish Council on Health Technology Assessment (SBU)	[Leukocytapheresis in inflammatory bowel disease (primarily ulcerative colitis)]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lenvatinib for iodine-refractory differentiated thyroid cancer]
2019	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (renal cell carcinoma): benefit assessment according to §35a Social Code Book V]
2022	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57]
2022	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[LEG TEST. Multi centre testing of the Lively Legs program for promoting compliance with compression therapy and prescribed exercise in leg ulcer patients]
2018	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Left ventricular assist device (LVAD) as destination therapy]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ledipasvir/sofosbuvir (hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2009	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Lead extraction of pacemaker or implantable cardiac defibrillator leads using laser excimer]